Dengue subunit vaccine - Merck Sharp and Dohme
Alternative Names: DEN 1 80E; Dengue subunit vaccine - Hawaii Biotech; HB6; HBV-001 D1; Tetravalent dengue vaccine - Merck Sharp & Dohme; V 180Latest Information Update: 28 Mar 2022
At a glance
- Originator Hawaii Biotech
- Developer Merck Sharp & Dohme; National Institute of Allergy and Infectious Diseases
- Class Dengue vaccines; Subunit vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dengue
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for phase-I development in Dengue(In volunteers) in Australia (IM, Injection)
- 28 Mar 2022 No recent reports of development identified for phase-I development in Dengue(In volunteers) in USA (IM, Injection)
- 27 Feb 2020 Phase-I development is ongoing in Dengue in Australia